Debug information for CIK 1800, Year 2016

Filing URL: https://www.sec.gov/Archives/edgar/data/1800/000104746916010246/a2227279z10-k.htm
Filing Date: 02/19/2016
Reporting Date: 12/31/2015

First 1000 characters of text:

10-K
1
a2227279z10-k.htm
10-K




 








   
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549






FORM 10-K  











(MARK ONE)
 
 


ý
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934


 OR


o
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934





















For the fiscal year ended December 31, 2015
 
Commission file number 1-2189




Abbott Laboratories  











An Illinois Corporation
 
 36-0698440


100 Abbott Park Road
Abbott Park, Illinois 60064-6400
 
 (I.R.S. employer identification number) (224) 667-6100 (telephone number)




Securities Registered Pursuant to Section 12(b) of the Act:  











 


Title of Each Class
 
Name of Each Exchange on Which Registered


 


Common Shares, Without Par Value
  
 
 New York Stock Exchange
Chicago Stock Exchange


 




Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in 

Risk Factor Section Found

First 1000 characters of risk section:
<html><body><br/>
<p style="font-family:times;text-align:justify"><font size="2">        In addition to the other information in this report, the following risk factors should be considered before deciding to invest in any
of Abbott's securities. Additional risks and uncertainties not presently known to Abbott, or risks Abbott currently considers immaterial, could also affect Abbott's actual results. Abbott's business,
financial condition, results of operations, or prospects could be materially adversely affected by any of these risks. </font></p>
<p style="font-family:times;text-align:justify;margin-left:0pt;text-indent:-0pt;"><font size="2"><b>
<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Abbott may acquire other businesses, license rights to technologies or products, form alliances, or
dispose of or spin-off businesses, which could cause it to incur significant expenses and could negatively affect profitability.  </b></font></p>
<p style="font-family:times;text

Found 20 risk factor titles:
1. Abbott may acquire other businesses, license rights to technologies or products, form alliances, or dispose of or spin-off businesses, which could cause it to incur significant expenses and could negatively affect profitability.
2. Abbott is subject to cost containment efforts that could cause a reduction in future revenues and operating income.
3. Abbott is subject to numerous governmental regulations and it can be costly to comply with these regulations and to develop compliant products and processes.
4. Laws and regulations affecting government benefit programs could impose new obligations on Abbott, require Abbott to change its business practices, and restrict its operations in the future.
5. Changes in the health care regulatory environment may adversely affect Abbott's business.
6. The expiration or loss of patent protection and licenses may affect Abbott's future revenues and operating income.
7. Competitors' intellectual property may prevent Abbott from selling its products or have a material adverse effect on Abbott's future profitability and financial condition.
8. Abbott's research and development efforts may not succeed in developing commercially successful products and technologies, which may cause Abbott's revenue and profitability to decline.
9. New products and technological advances by Abbott's competitors may negatively affect Abbott's results of operations.
10. The manufacture of many of Abbott's products is a highly exacting and complex process, and if Abbott or one of its suppliers encounters problems manufacturing products, Abbott's business could suffer.
11. Significant safety concerns could arise for Abbott's products, which could have a material adverse effect on Abbott's revenues and financial condition.
12. Deterioration in the economic position and credit quality of certain countries may negatively affect Abbott's results of operations.
13. Abbott depends on sophisticated information technology systems and a cyber attack or other breach of these systems could have a material adverse effect on Abbott's results of operations.
14. Abbott may incur operational difficulties or be exposed to claims and liabilities as a result of the separation.
15. There could be significant liability if the distribution of AbbVie common stock to Abbott shareholders is determined to be a taxable transaction.
16. Abbott holds a significant investment in Mylan N.V. and is subject to market risk.
17. Fluctuation in foreign currency exchange rates may adversely affect our financial statements and Abbott's ability to realize projected sales and earnings.
18. The international nature of Abbott's business subjects it to additional business risks that may cause its revenue and profitability to decline.
19. Other factors can have a material adverse effect on Abbott's future profitability and financial condition.
20. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
